PhD, Assistant Professor of Human Anatomy, University of Bologna
Group Leader at the Cellular Signalling Laboratory of the Department of Anatomical Sciences, University of Bologna
1985-1990 Studies of Biological Science at the University of Bologna, Italy
1990 State Biological Examination and License
1998 PhD in Biochemistry , Department of Biochemistry "G. Moruzzi" University
1999-2004 Post-doctoral fellow, Department of Biomedical Sciences, section of Human Anatomy Bologna University
2005 Confirmed Researcher, Department of Biomedical Sciences, section of Human Anatomy Bologna University
2012 She holds the National Scientific Enabling Associate Professor in the competitive sector 05H1 BIO/16
2014 Associate Professor, Department of Biomedical Sciences, section of Human Anatomy Bologna University
2018 She holds the National Scientific Enabling Full Professor in the competitive sector 05H1 BIO/16
The research of Dr. Irene Faenza is directed mainly to the study of the mechanisms underlying the growth and differentiation in relation to signals generated by the nuclear cycle polyphosphoinositide (PI) and the morphological and functional significance of the topography of this system signal transduction. Her studies focus on nuclear enzymes that metabolize PI and in particular is interested in the study of Phospholipase C inositide dependent. The studies conducted so far by Dr. Irene Faenza are geared to deepen the role in the nucleus polyphosphoinositide and identify specific targets of PLCb1. All these studies have contributed greatly to the identification and determination of the functional role of the nuclear cycle polyphosphoinositide in both differentiation and proliferation processes. Especially it was highlighted the importance of topographical subcellular localization and determination of specific functions of signaling inositide-dependent. For this reason these works have been cited in the most important articles and reviews by the leading experts in the field. Her work covers the following fields: Autonomous nuclear signalling via inositol lipid cycle, is aimed to the identification at nuclear level of the key steps leading to cell growth and differentiation. In particular the main interest is the study in normal and cancer cells of the nuclear localisation and signalling activity of polyphosphoinositides. She has contributed to the discovery of the localisation at the nucleus of this signalling pathway, as internationally recognised, and currently she is furthering the pathophysiological significance of this peculiar location. Through morpho functional studies both in the differentiation and proliferation processes it was identified cyclin D3 as a final target of this nuclear lipid signaling. In recent years Dr Irene Faenza is dedicated to investigations in the field of functional proteomics for the identification of proteins that interact at the nuclear level with PLCβ1 and for the determination of its molecular targets. Recently Dr. Faenza is dedicated to the study and analysis of miRNAs. In mammals, miRNAs are involved in embryonic development, neural and muscle but also in the regulation of hematopoiesis, of 'organogenesis and apoptosis. Dr. Faenza is dedicated to the development of a project which envisaged to identify miRNAs involved in erythroid differentiation following the differentiation of K562 which had been modulated the expression of PLCβ1. In particular since the last years her main interest is the study of the nuclear localisation and signalling activity and the identification of novel downstream effectors of nuclear polyphosphoinositides also through the high-resolution 2-DE-based proteomic analysis. Namely she has furtherd the role of this signalling pathway in the nucleus during myogenic differentiation, giving new insight to its role in myotonic dystrophies. Moreover she has contributed to the study of haemopoietic differentiation, envisaging the pathophysiological significance of nuclear phosphoinositide signalling in MDS. Very recently she has investigated the mechanism of osteogenic differentiation to clarify the molecular events which control this process. AKT regulates many cellular functions, such as growth and proliferation and differentiation. Dr Faenza has contributed to identify the nuclear substrates of AKT that were phosphorylated after ATRA treatment through a proteomics-based analysis by using 2D-electrophoresis/mass spectrometry (MS) in combination with an anti-AKT phospho-substrate antibody. Furthermore research has been conducted to elucidate the nuclear role of the double-strand RNA-dependent protein kinase, PKR, which plays a central role in inflammatory/chronic stress-mediated pathologies such as cancer, diabetes, and neuro/muscular degenerative diseases.
: Impact Factor of papers on peer reviewed journals (JCR-ISI 2007)= 153.64 . Total cites last 10 years
(JCR-ISI 2007)= 725
International meetings attended :
1997 FEBS Special Meet. On Mechanism of Cell Signaling, Amsterdam (Netherlands)
1999 FEBS Advance Course "Targets and Functions of Lipid-derived Messengers" June
11-16, Mario Negri Sud, Italy
2002 ELSO conference Nice, France 29th June to 3rd July 2002
2005 The Gordon Research Conference :"Signal transduction within the nucleus" Santa
Ynez Valley, S.Barbara, CA,USA February 6-11, 2005
2007 The Gordon Research Conference :"Signal transduction within the nucleus" Crown
Plaza Ventura, California march 25-30, 2007
2008 FASEB Sum. Conf."Phospholipid Metabolism: Disease, Signal Transduction and
Membrane Dinamics, New Haven, Connecticut July 20-25, 2008
Since 2006 she is recipient of Research funds from University of Bologna as group leader for the project dealing with nuclear signalling.
2001-2005 participates in the National Program Italian MIUR-Cofin and in particular to the following national research projects, selected for funding based on competitive calls providing peer review:
FIRB 2001-2003, Protocol: RBNE0189JJ-002 (18 months as a fellow)
PRIN 2005 Protocol: 2005055737 to 001 (12 months as a researcher)
FIRB program agreements 2010, Protocol RBAP10447J-001 (8 months as a researcher)
FIRB, RN Proteomics, Protocol: RBRN07BMCT-002 (8 months as a researcher)
Institutional and organizational activities
-She is a member since 2005 of the Italian Society of Anatomy and Histology and of the Italian Society of Histochemistry.
-She participated actively in the Congress of the Italian Society of Anatomy and Histochemistry, presenting communications and posters.
-Collaborates organization of the Proteomics Center c / o the laboratory signaling section of the IOR (Istuti Ortopedici Rizzoli) DIBINEM
-Member of the "Pedagogical Technical Commission" of the degree course in Medicine and Surgery
-Coordinator of the Master of Science in Medical Biotechnology of the School of Medicine.
-Commissioner in degree examinations of CDL in Nursing (for certified professional nurses) at the campus of Rimini.
-Member of the Teaching Staff of the PhD in Biomedical and Neuromotor Sciences .
- "Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells".Bavelloni A, Faenza I. et al. Proteomics. 2006 Nov;6(21):5725-34, This article has been recognized publication of the images on the cover of the Journal.
- eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser53 is a novel substrate for protein kinase C βI. Piazzi M, Bavelloni A, Faenza I, Blalock W, Urbani A, D'aguanno S, Fiume R, Ramazzotti G, Maraldi Nm, Cocco L (2010). MOLECULAR & CELLULAR PROTEOMICS, vol. 9, p. 2719-2728, ISSN: 1535-9476, This article has been recognized publication of the images on the cover of the Journal.
3. "A role for nuclear phospholipase Cbeta 1 in cell cycle control". J Biol Chem. 2000 Sep 29;275(39):30520-4. Faenza I, et al. It was included in the section of the journal Science STKE (Editors' Choice Transcriptional Regulation by the Nuclear Phosphoinositide Cycle Sci. STKE 2000 (52), tw7. [DOI:10.1126/stke.2000.52.tw7] (3 Oct 2000), as one of the most original and important paper in the field of signal transduction and in particular of the nuclear lipid signaling.
72: Cocco L, Manzoli L, Faenza I, Ramazzotti G, Yang YR, McCubrey JA, Suh PG, Follo MY. Modulation of nuclear PI-PLCbeta1 during cell differentiation. Adv Biol Regul. 2015 Oct 26. pii: S2212-4926(15)30035-X. doi: 10.1016/j.jbior.2015.10.008.
71: Ramazzotti G, Bavelloni A, Blalock W, Piazzi M, Cocco L, Faenza I. BMP-2 Induced Expression of PLCβ1 That is a Positive Regulator of Osteoblast Differentiation. J Cell Physiol. 2016 Mar;231(3):623-9. (IF:4,218)
70: Bavelloni A, Piazzi M, Raffini M, Faenza I, Blalock WL. Prohibitin 2: At a communications crossroads. IUBMB Life. 2015 Apr;67(4):239-54. (IF: 3.143)
69: Piazzi M, Blalock WL, Bavelloni A, Faenza I, Raffini M, Tagliavini F, Manzoli L, Cocco L. PI-PLCβ1b affects Akt activation, cyclin E expression, and caspasecleavage, promoting cell survival in pro-B-lymphoblastic cells exposed tooxidative stress. FASEB J. 2015 Apr;29(4):1383-94. doi: 10.1096/fj.14-259051. (IF: 5,704)
68: Bavelloni A, Dmitrienko GI, Goodfellow VJ, Ghavami A, Piazzi M, Blalock W, Chiarini F, Cocco L, Faenza I. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. J Cell Physiol. 2015 Mar;230(3):587-94. doi: 10.1002/jcp.24776. (IF:4,218)
67: Bavelloni A, Poli A, Fiume R, Blalock W, Matteucci A, Ramazzotti G, McCubrey JA, Cocco L, Faenza I. PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget. 2014 Jun 30;5(12):4222-31. (IF: 6,63)
66: Bavelloni A, Piazzi M, Faenza I, Raffini M, D'Angelo A, Cattini L, Cocco L, Blalock WL. Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. FASEB J. 2014 Feb 12. (IF: 5,704)
65: Blalock WL, Piazzi M, Bavelloni A, Raffini M, Faenza I, D'Angelo A, Cocco L. Identification of the PKR Nuclear Interactome Reveals Roles in Ribosome Biogenesis, mRNA Processing and Cell Division. J Cell Physiol. 2013 Dec 18. doi: 10.1002/jcp.24529. (IF:4,218)
64: Follo MY, Faenza I, Piazzi M, Blalock WL, Manzoli L, McCubrey JA, Cocco L. Nuclear PI-PLCβ1: an appraisal on targets and pathology. Adv Biol Regul. 2014 Jan;54:2-11. doi: 10.1016/j.jbior.2013.11.003. Epub 2013 Nov 20. PubMed PMID: 24296032.
63: Faenza I, Fiume R, Piazzi M, Colantoni A, Cocco L. Nuclear inositide specific phospholipase C signalling - interactions and activity. FEBS J. 2013 Dec;280(24):6311-21. doi: 10.1111/febs.12450. Epub 2013 Aug 20. Review. PubMed PMID: 23890371. (IF:4,25)
62: Piazzi M, Blalock WL, Bavelloni A, Faenza I, D'Angelo A, Maraldi NM, Cocco L. Phosphoinositide-specific phospholipase C β 1b (PI-PLCβ1b) interactome: affinity purification-mass spectrometry analysis of PI PLCβ1b with nuclear protein. Mol Cell Proteomics. 2013 Aug;12(8):2220-35. doi:10.1074/mcp.M113.029686. Epub 2013 May 9. PubMed PMID: 23665500; PubMed Central PMCID: PMC3734581. (IF: 7,398)
61: Poli A, Faenza I, Chiarini F, Matteucci A, McCubrey JA, Cocco L. K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway. Cell Cycle. 2013 Jun 1;12(11):1713-21. doi: 10.4161/cc.24806. Epub 2013 May 6. PubMed PMID: 23656785; PubMed Central PMCID: PMC3713130. (IF: 5.24)
60: Follo MY, Marmiroli S, Faenza I, Fiume R, Ramazzotti G, Martelli AM, Gobbi P, McCubrey JA, Finelli C, Manzoli FA, Cocco L. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. Adv Biol Regul. 2013 Jan;53(1):2-7.doi: 10.1016/j.jbior.2012.09.009. Epub 2012 Sep 21. Review. PubMed PMID:23058275.
59: Faenza I, Blalock W, Bavelloni A, Schoser B, Fiume R, Pacella S, Piazzi M, D'Angelo A, Cocco L. A role for PLCβ1 in myotonic dystrophies type 1 and 2. FASEB J. 2012 Jul;26(7):3042-8. doi: 10.1096/fj.11-200337. Epub 2012 Mar 29. PubMedPMID: 22459146.(IF: 5,704)
58: Fiume R, Keune WJ, Faenza I, Bultsma Y, Ramazzotti G, Jones DR, Martelli AM, Somner L, Follo MY, Divecha N, Cocco L. Nuclear phosphoinositides: location,regulation and function. Subcell Biochem. 2012;59:335-61. doi: 10.1007/978-94-007-3015-1_11. PubMed PMID: 22374096.
57: Follo MY, Mongiorgi S, Finelli C, Piazzi M, Faenza I, Ramazzotti G, Santi P, McCubrey JA, Martelli AM, Cocco L. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics. Curr Pharm Des. 2012;18(13):1751-4. Review. PubMed PMID: 22352752. (IF: 3,311)
56: Ramazzotti G, Faenza I, Follo MY, Fiume R, Piazzi M, Giardino R, Fini M, Cocco L. Nuclear phospholipase C in biological control and cancer. Crit RevEukaryot Gene Expr. 2011;21(3):291-301. Review. PubMed PMID: 22111715. (IF: 2,07)
55: Follo MY, Faenza I, Fiume R, Ramazzotti G, McCubrey JA, Martelli AM, Manzoli FA, Cocco L. Revisiting nuclear phospholipase C signalling in MDS. Adv Biol Regul. 2012 Jan;52(1):2-6. Review. PubMed PMID: 21982979.
54: Fiume R, Ramazzotti G, Faenza I, Piazzi M, Bavelloni A, Billi AM, Cocco L. Nuclear PLCs affect insulin secretion by targeting PPARγ in pancreatic β cells. FASEB J. 2012 Jan;26(1):203-10. (IF: 5,704)
53: Blalock WL, Bavelloni A, Piazzi M, Tagliavini F, Faenza I, Martelli AM, Follo MY, Cocco L. Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. Leukemia. 2011 Feb;25(2):236-45.(IF: 10,64)
52: Cocco L, Follo MY, Faenza I, Fiume R, Ramazzotti G, Weber G, Martelli AM, Manzoli FA. Physiology and pathology of nuclear phospholipase C β1. Adv Enzyme Regul. 2011;51(1):2-12.
51: Piazzi M, Bavelloni A, Faenza I, Blalock W, Urbani A, D'Aguanno S, Fiume R, Ramazzotti G, Maraldi NM, Cocco L. eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser⁵³ is a novel substrate for protein kinase C βI. Mol Cell Proteomics. 2010 Dec;9(12):2719-28. (IF: 7,398)
50: Ramazzotti G*, Faenza I*, Fiume R, Matteucci A, Piazzi M, Follo MY, Cocco L. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol. 2011 Jan;226(1):14-20. (IF:4,218) *contributed equally to this work
49: Fiume R, Teti G, Faenza I, Cocco L. Phosphoinositide-specific phospholipase C beta1 signal transduction in the nucleus. Methods Mol Biol. 2010;645:143-64.
48: Blalock WL, Bavelloni A, Piazzi M, Faenza I, Cocco L. A role for PKR in hematologic malignancies. J Cell Physiol. 2010 Jun;223(3):572-91. (IF:4,218)
47: Follo MY, Mongiorgi S, Finelli C, Clissa C, Ramazzotti G, Fiume R, Faenza I, Manzoli L, Martelli AM, Cocco L. Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem. 2010 Apr 15;109(6):1065-71.(IF: 3,062)
46: Bertagnolo V, Grassilli S, D'Aguanno S, Brugnoli F, Bavelloni A, Faenza I,Nika E, Urbani A, Cocco L, Capitani S. Mass spectrometry-based identification of Y745 of Vav1 as a tyrosine residue crucial in maturation of acute promyelocytic leukemia-derived cells. J Proteome Res. 2010 Feb 5;9(2):752-60. (IF: 5,506)
45: Gaboardi GC, Ramazzotti G, Bavelloni A, Piazzi M, Fiume R, Billi AM,Matteucci A, Faenza I, Cocco L. A role for PKCepsilon during C2C12 myogenic differentiation. Cell Signal. 2010 Apr;22(4):629-35. (IF: 4,060)
44: Cocco L, Follo MY, Faenza I, Billi AM, Ramazzotti G, Martelli AM, Manzoli L, Weber G. Inositide signaling in the nucleus: from physiology to pathology. Adv Enzyme Regul. 2010;50(1):2-11.
43: O'Carroll SJ, Mitchell MD, Faenza I, Cocco L, Gilmour RS. Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. Cell Signal. 2009 Jun;21(6):926-35. PubMed PMID:19385066. (IF: 4,060)
42: Cocco L, Faenza I, Follo MY, Billi AM, Ramazzotti G, Papa V, Martelli AM, Manzoli L. Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. Adv Enzyme Regul. 2009;49(1):2-10.
41: Fiume R, Ramazzotti G, Teti G, Chiarini F, Faenza I, Mazzotti G, Billi AM, Cocco L. Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. FASEB J. 2009 Mar;23(3):957-66 (IF: 5,704)
40: Ramazzotti G*, Faenza I*, Gaboardi GC, Piazzi M, Bavelloni A, Fiume R, Manzoli L, Martelli AM, Cocco L. Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. Cell Signal. 2008 Nov;20(11):2013-21. * contributed equally to this work (IF: 4,060)
39: Cocco L, Faenza I, Follo MY, Ramazzotti G, Gaboardi GC, Billi AM, Martelli AM, Manzoli L. Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. Adv Enzyme Regul. 2008;48:2-9.
38: Faenza I, Bregoli L, Ramazzotti G, Gaboardi G, Follo MY, Mongiorgi S, Billi AM, Manzoli L, Martelli AM, Cocco L. Nuclear phospholipase C beta1 and cellular differentiation. Front Biosci. 2008 Jan 1;13:2452-63. Review. PubMed PMID:17981726.(IF:3,063)
37: Cocco L, Follo MY, Faenza I, Bavelloni A, Billi AM, Martelli AM, Manzoli L. Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells. Adv Enzyme Regul. 2007;47:2-9.
36: Faenza I, Ramazzotti G, Bavelloni A, Fiume R, Gaboardi GC, Follo MY, Gilmour RS, Martelli AM, Ravid K, Cocco L. Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology. 2007 Mar;148(3):1108-17 (IF: 4,833)
35: Bavelloni A, Faenza I, Cioffi G, Piazzi M, Parisi D, Matic I, Maraldi NM, Cocco L. Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. Proteomics. 2006 Nov;6(21):5725-34. (IF: 4,132)
34: Evangelisti C, Riccio M, Faenza I, Zini N, Hozumi Y, Goto K, Cocco L,Martelli AM. Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. J Cell Physiol. 2006 Nov;209(2):370-8. (IF:4,218)
33: Cocco L, Martelli AM, Fiume R, Faenza I, Billi AM, Manzoli FA. Signal transduction within the nucleus: revisiting phosphoinositide inositide-specific phospholipase Cbeta1. Adv Enzyme Regul. 2006;46:2-11. Epub 2006 Jul 18. Review.
32: Follo MY, Bosi C, Finelli C, Fiume R, Faenza I, Ramazzotti G, Gaboardi GC, Manzoli L, Cocco L. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med. 2006 Aug;18(2):267-71. (IF: 1.957)
31: Cocco L, Faenza I, Fiume R, Maria Billi A, Gilmour RS, Manzoli FA. Phosphoinositide-specific phospholipase C (PI-PLC) beta1 and nuclear lipid-dependent signaling. Biochim Biophys Acta. 2006 May-Jun;1761(5-6):509-21.Epub 2006 Mar 29. Review. (IF: 3,848)
30: Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Falà F, Cocco L. Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal. 2006 Aug;18(8):1101-7. (IF: 4,060)
29: Faenza I, Billi AM, Follo MY, Fiume R, Martelli AM, Cocco L, Manzoli L. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Anticancer Res. 2005 May-Jun;25(3B):2039-41. Review. (IF: 1,725)
28: Martelli AM, Fiume R, Faenza I, Tabellini G, Evangelista C, Bortul R, Follo MY, Falà F, Cocco L. Nuclear phosphoinositide specific phospholipase C(PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction. Histol Histopathol. 2005 Oct;20(4):1251-60. Review. PubMed PMID:16136505.(IF: 2,28)
27: Manzoli L, Martelli AM, Billi AM, Faenza I, Fiume R, Cocco L. Nuclear phospholipase C: involvement in signal transduction. Prog Lipid Res. 2005 Jul;44(4):185-206. (IF: 11,237)
26: Fiume R, Faenza I, Matteucci A, Astolfi A, Vitale M, Martelli AM, Cocco L. Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. J Biol Chem. 2005 Jun24;280(25):24221-6. (IF: 4,651)
25: Faenza I, Bavelloni A, Fiume R, Santi P, Martelli AM, Maria Billi A, Lo Vasco VR, Manzoli L, Cocco L. Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. J Cell Physiol. 2004 Aug;200(2):291-6. (IF:4,218)
24: Martelli AM, Falà F, Faenza I, Billi AM, Cappellini A, Manzoli L, Cocco L. Metabolism and signaling activities of nuclear lipids. Cell Mol Life Sci. 2004 May;61(10):1143-56. IF: 5.615)
23: Merlo Pich M, Raule N, Catani L, Fagioli ME, Faenza I, Cocco L, Lenaz G. Increased transcription of mitochondrial genes for Complex I in human platelets during ageing. FEBS Lett. 2004 Jan 30;558(1-3):19-22. (IF:4,25)
22: Martelli AM, Faenza I, Billi AM, Falà F, Cocco L, Manzoli L. Nuclear protein kinase C isoforms: key players in multiple cell functions? Histol Histopathol.2003 Oct;18(4):1301-12.(IF: 2.281)
21: Faenza I, Bavelloni A, Fiume R, Lattanzi G, Maraldi NM, Gilmour RS, Martelli AM, Suh PG, Billi AM, Cocco L. Up-regulation of nuclear PLCbeta1 in myogenic differentiation. J Cell Physiol. 2003 Jun;195(3):446-52. (IF:4,218)
20: Martelli AM, Manzoli L, Faenza I, Bortul R, Billi A, Cocco L. Nuclear inositol lipid signaling and its potential involvement in malignant transformation. Biochim Biophys Acta. 2002 Oct 2;1603(1):11-7. (I.F.: 10,11)
19: Martelli AM, Bortul R, Tabellini G, Faenza I, Cappellini A, Bareggi R, Manzoli L, Cocco L. Molecular characterization of protein kinase C-alpha binding to lamin A. J Cell Biochem. 2002;86(2):320-30.(I.F.: 3,06)
18: Faenza I, Matteucci A, Bavelloni A, Marmiroli S, Martelli AM, Gilmour RS, Suh PG, Manzoli L, Cocco L. Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in Friend erythroleukemia cells. Biochim Biophys Acta. 2002 May 8;1589(3):305-10. (I.F.: 4,94)
17: Ponti C, Falconi M, Billi AM, Faenza I, Castorina S, Caimi L, Cacchioli A, Cocco L, Vitale M. IL-12 and IL-15 induce activation of nuclear PLCbeta in human natural killer cells. Int J Oncol. 2002 Jan;20(1):149-53. (I.F.: 2,65)
16: Martelli AM, Billi AM, Manzoli L, Faenza I, Aluigi M, Falconi M, De Pol A, Gilmour RS, Cocco L. Insulin selectively stimulates nuclear phosphoinositide-specific phospholipase C (PI-PLC) beta1 activity through amitogen-activated protein (MAP) kinase-dependent serine phosphorylation. FEBS Lett. 2000 Dec 15;486(3):230-6. (IF:4,25)
15: Faenza I, Matteucci A, Manzoli L, Billi AM, Aluigi M, Peruzzi D, Vitale M,Castorina S, Suh PG, Cocco L. A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem. 2000 Sep 29;275(39):30520-4. (I.F.: 4,65)
14: Peruzzi D, Calabrese G, Faenza I, Manzoli L, Matteucci A, Gianfrancesco F,Billi AM, Stuppia L, Palka G, Cocco L. Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene ofphosphoinositide-specific phospholipase C beta(1). Biochim Biophys Acta. 2000 Apr 12;1484(2-3):175-82. (I.F.: 4,94)
13: Bavelloni A, Faenza I, Aluigi M, Ferri A, Toker A, Maraldi NM, Marmiroli S. Inhibition of phosphoinositide 3-kinase impairs pre-commitment cell cycle traverse and prevents differentiation in erythroleukaemia cells. Cell Death Differ. 2000 Jan;7(1):112-7. (I.F.: 8,37)
12: Manzoli L, Billi AM, Faenza I, Matteucci A, Martelli AM, Peruzzi D, Falconi M, Rhee SG, Gilmour RS, Cocco L. Nuclear phospholipase C: a novel aspect of phosphoinositide signalling. Anticancer Res. 1999 Sep-Oct;19(5A):3753-6. (I.F.: 1,7)
11: Cocco L, Rubbini S, Manzoli L, Billi AM, Faenza I, Peruzzi D, Matteucci A, Artico M, Gilmour RS, Rhee SG. Inositides in the nucleus: presence and characterisation of the isozymes of phospholipase beta family in NIH 3T3 cells. Biochim Biophys Acta. 1999 May 18;1438(2):295-9. P (I.F. 4,94)
10: Bavelloni A, Santi S, Sirri A, Riccio M, Faenza I, Zini N, Cecchi S, Ferri A, Auron P, Maraldi NM, Marmiroli S. Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells. J Cell Sci. 1999 Mar;112 ( Pt5):631-40. PubMed PMID: 9973598. (IF: 5.877)
9: Matteucci A, Faenza I, Gilmour RS, Manzoli L, Billi AM, Peruzzi D, Bavelloni A, Rhee SG, Cocco L. Nuclear but not cytoplasmic phospholipase C beta 1 inhibits differentiation of erythroleukemia cells. Cancer Res. 1998 Nov 15;58(22):5057-60.PubMed PMID: 9823310. (IF: 8,650)
8: Marmiroli S, Bavelloni A, Faenza I, Sirri A, Ognibene A, Cenni V, Tsukada J, Koyama Y, Ruzzene M, Ferri A, Auron PE, Toker A, Maraldi NM. Phosphatidylinositol3-kinase is recruited to a specific site in the activated IL-1 receptor I. FEBS Lett. 1998 Oct 30;438(1-2):49-54. PubMed PMID: 9821957. (IF:4,25)
7: Billi AM, Matteucci A, Faenza I, Manzoli L, Rubbini S, Gilmour RS, Rhee SG, Cocco L. Control of expression of PLCbeta1 by LAC repressor system: relationship between nuclear PLCbeta1 overexpression and growth factor stimulation. Biochem Biophys Res Commun. 1997 Dec 8;241(1):122-6. PubMed PMID: 9405244. (IF: 2.406)
6: Flamigni F, Faenza I, Marmiroli S, Stanic' I, Giaccari A, Muscari C, Stefanelli C, Rossoni C. Inhibition of the expression of ornithine decarboxylase and c-Myc by cell-permeant ceramide in difluoromethylornithine-resistant leukaemia cells. Biochem J. 1997 Jun 15;324 ( Pt 3):783-9. PubMed PMID: 9210401; PubMed Central PMCID: PMC1218493. (IF: 4.654)
5: Manzoli L, Billi AM, Rubbini S, Bavelloni A, Faenza I, Gilmour RS, Rhee SG, Cocco L. Essential role for nuclear phospholipase C beta1 in insulin-like growth factor I-induced mitogenesis. Cancer Res. 1997 Jun 1;57(11):2137-9. PubMed PMID: 9187110. (IF: 8,650)
4: Zini N, Sabatelli P, Faenza I, Ognibene A, Maraldi NM. Interleukin-1 alpha induces variations of the intranuclear amount of phosphatidylinositol 4,5-bisphosphate and phospholipase C beta 1 in human osteosarcoma Saos-2 cells. Histochem J. 1996 Jul;28(7):495-504. PubMed PMID: 8872139. (IF: 1,5)
3: Marmiroli S, Zini N, Bavelloni A, Faenza I, Ognibene A, Maraldi NM. Transfected Saos-2 cells overexpressing phosphoinositidase C beta 1 isoformaccumulate it within the nucleus. Biol Cell. 1996;86(2-3):121-6. PubMed PMID:8893501.(IF: 3.488)
2: Zini N, Ognibene A, Marmiroli S, Bavelloni A, Maltarello MC, Faenza I, Valmori A, Maraldi NM. The intranuclear amount of phospholipase C beta 1 decreases following cell differentiation in Friend cells, whereas gamma 1 isoformis not affected. Eur J Cell Biol. 1995 Sep;68(1):25-34. PubMed PMID: 8549587.(IF: 3.213)
1: Falcieri E, Gobbi P, Cataldi A, Zamai L, Faenza I, Vitale M. Nuclear pores in the apoptotic cell. Histochem J. 1994 Sep;26(9):754-63. PubMed PMID: 7843986. (IF: 1,5)